ABOUT NANOLOGICA

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers.

Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity.

The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.

The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.

NLAB Saga®
A NEW GENERATION SILICA FOR PREPARATIVE CHROMATOGRAPHY

NLAB Saga® is a perfectly spherical, fully porous silica with superior mechanical stability and exceptional
chemical stability at high and low pH, making it an
optimum choice for large scale purification of peptides.

News

Nanologica AB Receives Order Worth USD 180,000 from New Customer in China

Nanologica has received an order for the company’s silica-based purification media NLAB Saga® from a new customer in China. The customer is a large pharmaceutical manufacturer, and the order relates to evaluation of NLAB Saga® on a production scale. The order, which is worth USD 180,000, will be delivered during the second quarter. ”This is

Read more »

Interim Report Q1 2025

FINANCIAL SUMMARY Net sales for the first quarter amounted to SEK 10,751 thousand (5,037) The operating loss amounted to SEK 9,241 thousand (15,331) Loss after tax amounted to SEK 10,171 thousand (16,734) Earnings per share before and after dilution were SEK -0.12 (-0.46) Cash and cash equivalents per 31 March 2024 amounted to SEK 28,348

Read more »

Listen to our team talk about Nlab Saga®

Interview with Katarina Alenäs,
SVP Chromatography

Interview with Olga Krivosheeva, Ph.D.
Application Project Manager 

Interview with Chunfang Zhou, Ph.D.
Sales Manager China

Nanologica is a public company listed for trade on Nasdaq Stockholm Main Market. For information regarding financial reports, press releases, presentations and share holder information, please visit our investor relations section.

Presentation of Nanologica

For more videos presentations of the company and of interim reports, please refer to Investor Relations.

Company presentation made by CEO Andreas Bhagwani in June, 2023.

Investor Pitch Deck November 2024.

Please contact us at ir@nanologica.com for more information.